Biotechnology

Brexogen's Exosome Therapy for Atopic Dermatitis, 'BRE-AD01' Accepted for Phase 1 Clinical Trials by US FDA

First entry to clinical trial of exosome for atopic dermatitis The first exosome-based therapeutics in US clinical trial among Korean companies SEOUL, South Korea, Nov. 7, 2022 /PRNewswire/ -- The US FDA granted the initiation of the phase 1 clinical trial of 'BRE-AD01', an exosome- based ther...

2022-11-07 07:00 1824

Telix Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study

Summary of Study Outcomes * ZIRCON Phase III study of Telix's investigational imaging agent TLX250-CDx in clear cell renal cell carcinoma (ccRCC) has met all of its primary and secondary endpoints * The study delivered co-primary endpoints of 86% sensitivity and 87% specificity and 93% posit...

2022-11-07 06:48 1635

TurtleTree to Represent Singapore at UN Climate Change Conference 2022 as Official Drink Partner

SHARM EL-SHEIKH, Egypt and SINGAPORE, Nov. 5, 2022 /PRNewswire/ -- TurtleTree will beSingapore's official drink partner at this year's UN Climate Change Conference(COP27), taking place from 6 to 18 November in Sharm El-Sheikh, Egypt.

2022-11-05 02:53 3450

Certa Therapeutics' investigational drug FT011 delivers breakthrough results as a potential novel treatment for serious inflammatory and fibrotic diseases

* Research presented today by University of Michigan Medical School highlights FT011's ground-breaking treatment potential from human expression profiles in chronic kidney disease study supported by animal model data * The research demonstrated that treatment with FT011 results in a remarkable...

2022-11-04 20:00 2178

NSW Health & Cicada Innovations celebrate Australia's biggest health startup training program with 1.1k participants in first year

SYDNEY, Nov. 4, 2022 /PRNewswire/ -- The NSW Health Commercialisation Training Program  (CT Program), delivered by Aust...

2022-11-04 11:35 2449

LUMC to Fund New Clinical Trial of Cynata's Cymerus™ MSCs in Kidney Transplantation

Key Highlights: * Cynata to collaborate with Leiden University Medical Center (LUMC) in the Netherlands, in a new clinical trial in patients who have received a kidney transplant * Trial to be funded by LUMC; Cynata will supply iPSC-derived Cymerus mesenchymal stem cells (MSCs) at its cost t...

2022-11-04 09:15 2615

Aquavit Celebrates Judgment Imposing Permanent Ban On Counterfeiters

NEW YORK, Nov. 4, 2022 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. ("Aquavit") secured a long-awaited and much-deserved judgment against counterfeiters. After nearly four years of court proceedings, the Honorable Valerie E. Caproni ofthe United States District Court for the Southern District o...

2022-11-04 01:37 2675

Kira Pharmaceuticals Presents Complete Data from Phase 1 SYNERGY-1 Trial of KP104 at American Society for Nephrology Kidney Week 2022

Biomarker data demonstrates proof-of-concept for KP104's dual-targeting mechanism via dose-dependent inhibition of alternative and terminal pathways and supports intravenous and subcutaneous administration of KP104 in phase 2 studies CAMBRIDGE, Mass. and SUZHOU, JIANGSU, China, Nov. 3, 2022 /PRN...

2022-11-03 21:30 2259

Gracell Biotechnologies to Present First Clinical Data of FasTCAR-T GC012F for Newly Diagnosed Multiple Myeloma at 64th American Society of Hematology Annual Meeting & Exposition

BCMA/CD19 dual-targeting FasTCAR-T GC012F demonstrated 100% ORR and 100% MRD negativity in the 13 patients treated SAN DIEGO, Calif., SUZHOU and SHANGHAI, China, Nov. 3, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharm...

2022-11-03 21:10 1821

Yuyu Pharma attendance at European Pharmaceutical Conference

SEOUL, South Korea, Nov. 3, 2022 /PRNewswire/ -- Robert Yu, CEO of Yuyu Pharma, has been attending biopharmaceutical conferences held inGermany, BIO-Europe and CPHI. The purpose is to explore opportunities to expand into international markets, such as Europe. 

2022-11-03 21:00 1670

Five New Drug Candidates Show Promise as Ainos Pursues Licensing Partners of its Low-dose Oral Interferon Formulation

The FDA gave positive feedback regarding filing a Biologics License Application (BLA) for Sjögren's syndrome following two Phase 3 studies Ainos is seeking out-licensing opportunities to accelerate the process of bringing five new drug candidates to Phase 3 trials and eventual commercialization ...

2022-11-03 19:00 1444

DOUBLE HONORS FOR AMGEN WITH GREAT PLACE TO WORK™ CERTIFICATIONS FOR BOTH ITS SINGAPORE ENTITIES IN 2022

SINGAPORE, Nov. 3, 2022 /PRNewswire/ -- Amgen announced both its entities in Singapore - Amgen Singapore Manufacturing (ASM) and its commercial affiliate Amgen Biotechnology Singapore (ABS), have been awarded Great Place to Work® certifications in the 'medium and large' workplace category for 202...

2022-11-03 16:43 3184

NeuroXess Shares Latest Breakthoughs in Life Sciences at Sequoia Talk

SHANGHAI, Nov. 3, 2022 /PRNewswire/ -- Peng Lei, CEO of NeuroXess, a Sequoia firm, was invited to participate in Sequoia China's Sequoia Talk Series on "The Compound Interest of Innovation" at which he shared his knowledge of and experience with the latest technological innovations in the field o...

2022-11-03 15:03 1865

Turn Biotechnologies Names 25-year Biotech Industry Veteran Richard Peterson Chief Financial Officer

Seasoned Executive has Successful Track Record Working with Global Investors to Raise Billions of Dollars MOUNTAIN VIEW, Calif., Nov. 2, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today annou...

2022-11-02 21:00 2566

Antengene Announces IND Approval for the Phase I STAMINA-001 Study to Evaluate ATG-037 (CD73 Inhibitor) for the Treatment of Locally Advanced or Metastatic Solid Tumors in China

-      ATG-037, an inhouse asset developed by Antengene and with global rights, has been approved to enter clinical studies inAustralia and China, thus becoming the firstoral small molecule CD73 inhibitor entering the clinical-stage in China and the wider Asia Pacific region. ATG-037 IND in Austr...

2022-11-02 20:07 2379

Dr Amit Kakar joins MedGenome Board of Directors

* The company has also added Navjeewan Khosla from Novo Holdings as Board Observer. * The company had announced a $50 million Series D investment led by Novo Holdings inAugust 2022. BANGALORE, India, Nov. 2, 2022 /PRNewswire/ -- MedGenome is a leading provider of genomic solutions for populat...

2022-11-02 10:00 1917

Ascletis Announces U.S. IND Filing of Oral 3CLpro Inhibitor ASC11 for COVID-19

-- ASC11 is an in-house discovered oral small molecule drug candidate, targeting 3-chymotrypsin like protease (3CLpro) -- In antiviral cellular assays with infectious SARS-CoV-2, ASC11 demonstrated higher potency against SARS-CoV-2 than other 3CLpro inhibitors including Nirmatrelvir, S-217622, P...

2022-11-02 08:10 2021

SK pharmteco appoints Joerg Ahlgrimm as CEO to spearhead the next phase of company growth and innovation

- Joerg Ahlgrimm brings 25 years of expertise in pharmaceuticals and innovative cell and gene therapies - SK pharmteco expands pharmaceutical drug production and advances cell and gene therapy production - Annual sales expected to exceed KRW 1 trillion in 2022 FRANKFURT, Germany, Nov. 2, 2022 /PR...

2022-11-02 02:00 1780

I Peace partners with the California Institute for Regenerative Medicine [CIRM]

PALO ALTO, Calif., Nov. 1, 2022 /PRNewswire/ -- I Peace, Inc. ( https://www.ipeace.com ) announced that the company has agreed to join the California Institute for Regenerative Medicine's (CIRM) Industry Resource Partner Program to pave way for the provision of Good Manuf...

2022-11-02 00:00 1996

Real-World Application of Lunit INSIGHT to be Spotlighted at RSNA 2022 (Oral Presentations)

* 7 oral presentations and 1 e-poster highlighting Lunit's most up-to-date research on its AI solution for radiology, have been accepted by RSNA * Program will include studies evaluating the performance of Lunit's commercial AI software across massive real-world population groups * Software ...

2022-11-01 22:00 2132
1 ... 100101102103104105106 ... 278